Galectin Therapeutics (GALT) Amortization of Deferred Charges (2018 - 2026)
Galectin Therapeutics' quarterly Amortization of Deferred Charges came in at $156000.0 in Q1 2026, down 55.04% year-on-year from $347000.0 in Q1 2025, and down 14.75% quarter-over-quarter from $183000.0 in Q4 2025.
Galectin Therapeutics has reported Amortization of Deferred Charges for 9 years, with the latest figure at $156000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 55.04% year-over-year to $156000.0; the trailing twelve-month figure through Mar 2026 stood at $903000.0 (down 27.12% YoY), and the FY2025 full-year result was $1.1 million, down 0.55% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $156000.0, down from $183000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $352000.0 in Q4 2024, with the low at $78000.0 in Q2 2022.
- Average Amortization of Deferred Charges over 5 years is $203352.9, with a median of $192000.0 recorded in 2023.
- Year-over-year, Amortization of Deferred Charges surged 972.73% in 2022 and plunged 55.04% in 2026.
- Tracing GALT's Amortization of Deferred Charges over 5 years: stood at $134000.0 in 2022, then jumped by 43.28% to $192000.0 in 2023, then jumped by 83.33% to $352000.0 in 2024, then sank by 48.01% to $183000.0 in 2025, then declined by 14.75% to $156000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $156000.0 (Q1 2026), $183000.0 (Q4 2025), and $215000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156,000.00 |
| Mar 31, 2026 | 156,000.00 |
| Dec 31, 2025 | 183,000.00 |
| Dec 31, 2025 | 183,000.00 |
| Sep 30, 2025 | 215,000.00 |
| Sep 30, 2025 | 215,000.00 |
| Jun 30, 2025 | 349,000.00 |
| Jun 30, 2025 | 349,000.00 |
| Mar 31, 2025 | 347,000.00 |
| Mar 31, 2025 | 347,000.00 |
| Dec 31, 2024 | 352,000.00 |
| Dec 31, 2024 | 352,000.00 |
| Sep 30, 2024 | 291,000.00 |
| Sep 30, 2024 | 291,000.00 |
| Jun 30, 2024 | 249,000.00 |
| Jun 30, 2024 | 249,000.00 |
| Mar 31, 2024 | 208,000.00 |
| Mar 31, 2024 | 208,000.00 |
| Dec 31, 2023 | 192,000.00 |
| Dec 31, 2023 | 192,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Jun 30, 2023 | 169,000.00 |
| Jun 30, 2023 | 169,000.00 |
| Mar 31, 2023 | 144,000.00 |
| Mar 31, 2023 | 144,000.00 |
| Dec 31, 2022 | 134,000.00 |
| Dec 31, 2022 | 134,000.00 |
| Sep 30, 2022 | 118,000.00 |
| Sep 30, 2022 | 118,000.00 |
| Jun 30, 2022 | 78,000.00 |
| Jun 30, 2022 | 78,000.00 |
| Mar 31, 2022 | 80,000.00 |
| Mar 31, 2022 | 80,000.00 |
| Dec 31, 2021 | 165,000.00 |
| Dec 31, 2021 | 165,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 85,000.00 |
| Jun 30, 2021 | 85,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Dec 31, 2020 | 23,000.00 |
| Dec 31, 2020 | 23,000.00 |
| Sep 30, 2020 | 21,000.00 |
| Sep 30, 2020 | 21,000.00 |
| Jun 30, 2020 | 21,000.00 |
| Jun 30, 2020 | 21,000.00 |
| Mar 31, 2020 | 22,000.00 |
| Mar 31, 2020 | 22,000.00 |
| Dec 31, 2019 | 22,000.00 |
| Dec 31, 2019 | 22,000.00 |
| Sep 30, 2019 | 22,000.00 |
| Sep 30, 2019 | 22,000.00 |
| Jun 30, 2019 | 21,000.00 |
| Jun 30, 2019 | 21,000.00 |
| Mar 31, 2019 | 22,000.00 |
| Mar 31, 2019 | 22,000.00 |
| Dec 31, 2018 | 80,000.00 |
| Dec 31, 2018 | 80,000.00 |
| Sep 30, 2018 | 87,000.00 |
| Sep 30, 2018 | 87,000.00 |
| Jun 30, 2018 | 85,000.00 |
| Jun 30, 2018 | 85,000.00 |
| Mar 31, 2018 | 84,000.00 |
| Mar 31, 2018 | 84,000.00 |